Analytik Jena Buys US Company and Sample Prep Company
An Analytik Jena spokesperson told IBO that the majority of the firm’s US revenue currently comes from its CyBio business. She said the UVP acquisition will generate sales synergies and allow Analytik to offer its entire Life Science portfolio in the US. Fiscal 2012 Life Science sales fell 0.4% to €28.2 million ($36.6 million = €0.77 = $1) to make up 30% of revenues. ETG will take over certain products lines of AJ Cybertron, a subsidiary that last year merged with Anaytik Jena. ETG’s headquarters in Ilmenau will become a competence center for automated sample handling.
Jena, Germany 4/2/13; Jena, Germany 4/10/13—Analytik Jena has agreed to acquire US-based UVP for an undisclosed amount. A supplier of digital imaging systems for proteomic, genomic and animal science applications, UVP posted fiscal 2012 sales of $17.2 million, with half of its sales generated in North America. Analytik Jena expects the acquisition to increase its Life Science business unit revenue and earnings. The business unit aims to be EBIT above breakeven in the second half of fiscal 2013 (ending September 30). In fiscal 2014, the business unit is expected to have sales of more than €40 million ($51 million = €.78 = $1), with an operating profit margin of 4%–7%. Analytik Jena also announced the acquisition of the remaining 80% stake in ETG Entwicklungs- und Technologie, which develops and assembles automated sample handling systems for analytical instruments, including atomic spectroscopy. Approximately 85% of ETG’s revenue comes from sales to Analytik Jena. Analytik Jena has owned 20% of ETG since 1991.
